Skip to main navigation Skip to search Skip to main content

Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia

  • Keqing Wang
  • , Shakil Ahmad
  • , Meng Cai
  • , Jillian Rennie
  • , Takeshi Fujisawa
  • , Fatima Crispi
  • , James Baily
  • , Mark R. Miller
  • , Melissa Cudmore
  • , Patrick W.F. Hadoke
  • , Rui Wang
  • , Eduard Gratacós
  • , Irina A. Buhimschi
  • , Catalin S. Buhimschi
  • , Asif Ahmed*
  • *Corresponding author for this work
  • Universitat Autònoma de Barcelona
  • Lakehead University
  • Yale University
  • University of Edinburgh

Research output: Contribution to journalArticlepeer-review

Abstract

Background-The exact etiology of preeclampsia is unknown, but there is growing evidence of an imbalance in angiogenic growth factors and abnormal placentation. Hydrogen sulfide (H2S), a gaseous messenger produced mainly by cystathionine γ-lyase (CSE), is a proangiogenic vasodilator. We hypothesized that a reduction in CSE activity may alter the angiogenic balance in pregnancy and induce abnormal placentation and maternal hypertension. Methods and Results-Plasma levels of H2S were significantly decreased in women with preeclampsia (P<0.01), which was associated with reduced placental CSE expression as determined by real-time polymerase chain reaction and immunohistochemistry. Inhibition of CSE activity by DL-propargylglycine reduced placental growth factorproduction from first-trimester (8-12 weeks gestation) human placental explants and inhibited trophoblast invasion in vitro. Knockdown of CSE in human umbilical vein endothelial cells by small-interfering RNA increased the release of soluble fms-like tyrosine kinase-1 and soluble endoglin, as assessed by enzyme-linked immunosorbent assay, whereas adenoviral-mediated CSE overexpression in human umbilical vein endothelial cells inhibited their release. Administration of DL-propargylglycine to pregnant mice induced hypertension and liver damage, promoted abnormal labyrinth vascularization in the placenta, and decreased fetal growth. Finally, a slow-releasing H2S-generating compound, GYY4137, inhibited circulating soluble fms-like tyrosine kinase-1 and soluble endoglin levels and restored fetal growth in mice that was compromised by DL-propargylglycine treatment, demonstrating that the effect of CSE inhibitor was attributable to inhibition of H2S production. Conclusions-These results imply that endogenous H2S is required for healthy placental vasculature and that a decrease in CSE/H2S activity may contribute to the pathogenesis of preeclampsia. © 2013 American Heart Association, Inc.

Original languageEnglish
Pages (from-to)2514-2522
Number of pages9
JournalCirculation
Volume127
Issue number25
Early online date23 May 2013
DOIs
Publication statusPublished - 25 Jun 2013

Bibliographical note

Funding: British Heart Foundation [PG/06/114]; Medical Research Council [G0601295, G0700288]

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • angiogenesis
  • fetal development
  • fms-like tyrosine kinase-1
  • hydrogen sulfide
  • placental growth factor
  • preeclampsia
  • vascular endothelial growth factor

Fingerprint

Dive into the research topics of 'Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia'. Together they form a unique fingerprint.

Cite this